To assess whether exogenous IgG4 antibodies could similarly modify the effector response of macrophages, we used two isotype variants of the anti-EGFR therapeutic anti-tumor antibody cetuximab, both with the same variable regions, but with γ1 or γ4 constant domains. Here, EGFR is linked to neoplasm.